Cascade Pharmaceuticals, Inc
Clinical trials sponsored by Cascade Pharmaceuticals, Inc, explained in plain language.
-
New hope for PBC patients: phase 3 trial of CS0159 launches
Disease control Recruiting nowThis study tests a new drug called CS0159 for people with primary biliary cholangitis (PBC), a liver disease, who either didn't get enough help from the standard medicine (UDCA) or couldn't take it. About 135 adults will receive either CS0159 or a placebo, and researchers will ch…
Phase: PHASE3 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New pill aims to shrink liver fat in NASH patients
Disease control Recruiting nowThis study tests a new tablet called CS060380 for people with non-alcoholic steatohepatitis (NASH), a serious liver condition. About 120 adults will take either the drug or a placebo daily for 12 weeks. Researchers will measure changes in liver fat using MRI and track any side ef…
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New pill could shrink fatty liver and help weight loss
Disease control Recruiting nowThis study tests an experimental drug called CS060380 in adults with both fatty liver disease (MASH) and obesity. About 120 participants will receive either the drug or a placebo, plus a weight-loss medication, for 36 weeks. The goal is to see if the drug reduces liver fat and bo…
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated May 20, 2026 11:57 UTC